← Browse by Condition
Medical Condition

unresectable solid tumor

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for unresectable solid tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — unresectable solid tumor Clinical Trials

How many clinical trials are currently recruiting for unresectable solid tumor?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for unresectable solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for unresectable solid tumor?
unresectable solid tumor research spans Phase 1 (2 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a unresectable solid tumor clinical trial?
Eligibility criteria for unresectable solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
1
Top Sponsors
Xinhua Zhang, MD 1 trial
Medicenna Therapeutics, Inc. 1 trial
Regor Pharmaceuticals Inc. 1 trial

Recruiting Clinical Trials

NCT05464875
Recruiting
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
Enrollment
74 pts
Location
China
Sponsor
Xinhua Zhang, MD
View Trial →
NCT05086692 Phase 1, Phase 2
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
Enrollment
115 pts
Location
United States, Austr...
Sponsor
Medicenna Therapeutics, Inc.
View Trial →
NCT07524322 Phase 1
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Enrollment
63 pts
Location
United States
Sponsor
Regor Pharmaceuticals Inc.
View Trial →

Related Conditions

cervical cancer (2) ovarian cancer (2) endometrial cancer (2) gastrointestinal stromal tumors (1) recurrent metastatic malignant neoplasm (1) advanced solid tumor (1) clear cell renal cell carcinoma (1) triple negative breast cancer (1) non small cell lung cancer squamous (1) non small cell lung cancer non squamous (1) colorectal cancer msi h (1) gastric cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology